BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld Asia
Home
» Synthetic antibody-based GPCR endocytosis inhibitor developed, study shows
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Synthetic antibody-based GPCR endocytosis inhibitor developed, study shows
Oct. 11, 2017
By
John Fox
No Comments
A new Indian study showing that selectively targeting signal-regulating proteins with intrabodies provides a novel means of fine-tuning G protein-coupled receptor (GPCR) functions has important implications for new drug development.
BioWorld Asia